Dr. David is CEO of Aspa Therapeutics and leads BridgeBio’s other gene therapy subsidiaries. A co-founder of Organovo, he most recently served as the company’s chief strategy officer and executive vice president of preclinical development. Prior to Organovo, Dr. David was an associate partner at McKinsey & Co., where he served stakeholders across the healthcare spectrum, including biopharmaceutical companies, private equity firms, large public and private healthcare systems, academic medical centers, and foundations, providing expertise on topics ranging from operations to M&A and R&D strategy. He was also assistant professor at The Rogosin Institute, adjunct faculty at The Rockefeller University and a lecturer in Medicine at Weil Cornell Medical College. Dr. David received his clinical training in internal medicine at New York-Presbyterian / Weill Cornell, his M.D. from Columbia University College of Physicians & Surgeons, and his law degree from Columbia Law School. He also holds a B.A. in physics and fine arts from Amherst College. He is licensed to practice medicine in California and New York, and is admitted to the bar in New York.